Angelini Pharma acquires Arvelle Therapeutics

Italian healthcare company Angelini Pharma said on Monday it would buy Swiss-based private equity-backed Arvelle Therapeutics in an all-cash transaction valuing the biopharmaceutical company up to $960 million.

The deal is the biggest acquisition ever for the 100-year old privately-held Italian group, which aims to become a leading player among companies focused on the central nervous system and mental health disorder treatments.

Arvelle has received investment from a global syndicate including NovaQuest Capital ManagementBRV Capital ManagementAndera Partners, and KB Investments.

Leave a Reply